Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab in a Real-World Setting: United States

NCT05388474 is registered in ClinicalTrials.gov with Theratechnologies as lead sponsor.

NCT NCT05388474
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05388474 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab in a Real-World Setting: United States
Lead sponsor
Theratechnologies
Phase
Observational
Overall status
Completed
Start date
March 22, 2022
Completion date
July 2, 2026
Enrollment
168 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections, multi-antiviral resistance